Dumolon, Lunabeth .

HRN: 22-20-09  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/27/2022
CO-AMOXICLAV 625MG (TAB)
12/27/2022
01/02/2023
PO
625
Bid
RMLE
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: